An expert panel has voted for the F.D.A to impose strict new limitations on the testosterone industry. The panel recommends that the agency tighten labels for the medicines so they are not prescribed to men who only have problems related to aging, such as low energy or libido. The agency will likely take the advice of the expert panel.
A recent study found that one of the oldest and most commonly used heart medications may shorten the lives of patients with atrial fibrillation, a common type of irregular heartbeat that affects about three million Americans.
Safety Announcement [7-3-2013] The U.S. Food and Drug Administration (FDA) is warning that the blood pressure drug olmesartan medoxomil (marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics) can cause intestinal problems known as sprue-like enteropathy. FDA has approved changes to the labels of these drugs to include this concern.
WARNING! On January 14, 2014 the FDA issued a safety alert with respect to drugs containing testosterone based on two published studies that suggested an increased risk of cardiovascular events among men who are prescribed testosterone therapy. These studies indicated that these drugs may increase the risk of ischemic stroke, heart attack or death.